There are three EGFR tyrosine kinase inhibitors (TKIs) approved for the first-line treatment of EGFR-mutated NSCLC: afatinib (Gilotrif), erlotinib, and gefitinib (Iressa), which target EGFR activating mutations (i.e., exon 19 deletion and exon 21 L858R). Here, EGFR is linked to non-small cell lung carcinoma.